Key Takeaways
- The House Veterans’ Affairs Subcommittee discussed the impact of FDA approval for psychedelic drugs on veteran mental health treatment.
- About 180,000 veterans might qualify for psychedelic-assisted therapy, but only a few hundred might receive it initially due to capacity issues.
- The VA currently conducts over 20 clinical trials on psychedelic therapies and aims to be prepared by establishing facilities and staff ahead of approval.
- Veterans groups call for readiness to ensure access and safety, emphasizing the importance of informed consent and quality care.
- Hearing concluded with lawmakers urging oversight and coordination to ensure timely implementation of therapies post-approval.
The House Veterans’ Affairs Subcommittee on Health spent roughly two and a half hours on a single question: what happens the day the FDA approves a psychedelic drug for mental health treatment. The hearing, titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward,” was led by Chairwoman Mariannette Miller-Meeks, a physician and 24-year Army veteran.
Miller-Meeks opened by citing the VA’s own suicide data. An average of 17 veterans died by suicide every day in 2024, more than 6,400 in a single year, and that number has stayed stagnant despite years of federal spending on mental health care. She argued that conventional treatment does not work for every veteran, and that if emerging therapies involving MDMA, psilocybin, or ibogaine can reduce suffering, the federal government has a responsibility to explore them.
Testifying for the department were Andrew Gratison, senior advisor to the Veterans Health Administration, and Dr. Ilse Wiechers, who leads VA’s psychedelics integrated project team. A second panel brought in outside experts: Dr. Leith States, a combat veteran and former HHS official; Dr. Marion Coe of Pinney Associates; Dr. Mark Niciu of the University of Iowa; and Dr. Raquel Halfond of the American Psychological Association, according to the House committee’s hearing record.
The tone was notably bipartisan. Ranking Member Julia Brownley called this “a very pivotal moment” for veterans, while Rep. Morgan Luttrell, who has publicly advocated for ibogaine access, pressed VA to move faster without cutting corners on safety.
How Many Veterans Could Qualify for Psychedelic-Assisted Therapy?
Gratison gave the subcommittee a specific number during questioning: roughly 180,000 veterans could meet the inclusion criteria used in VA’s current research protocols on day one of approval. That figure is drawn from about 2.1 million veterans currently diagnosed with treatment-resistant depression, major depressive disorder, or PTSD, filtered down using the same eligibility standards VA applies in its clinical trials.
Rep. Maggie Goodlander pushed further, noting that Gratison has previously said reaching even four digits of treated patients in year one would be a challenge. That gap, somewhere between 180,000 potentially eligible veterans and a few thousand who might actually receive care, became a recurring theme. Goodlander asked VA to commit to sharing a staffing plan for its initial sites within 30 days, covering how many clinicians are needed, where they will come from, and what it will cost. Gratison agreed to provide that information.
The math matters because it frames the entire debate. Even a successful FDA approval does not automatically translate into fast access. Workforce capacity, facility readiness, and referral pathways all have to scale at the same time, and right now VA’s own numbers suggest a significant mismatch between demand and supply.
Is the VA Already Running Psychedelic Clinical Trials?
Yes, on two fronts. According to written testimony from the Veterans of Foreign Wars submitted for the hearing, VA is involved in 20 active clinical trials on psychedelic therapies, backed by more than $23 million in external funding. Separately, in his spoken testimony, Gratison told the subcommittee that as of September 2026, VA was conducting 21 active clinical studies of psychedelic treatments, a close but distinct figure reflecting a slightly later snapshot.
Those studies include a randomized trial of MDMA-assisted therapy for PTSD and alcohol use disorder running at VA facilities in Rhode Island and Connecticut, and the PIVOT trial examining psilocybin for treatment-resistant depression. In August 2026, VA launched an additional psilocybin trial covering major depressive disorder, including veterans with concurrent PTSD.
Three compounds, MDMA, psilocybin, and ibogaine, currently have pending new drug applications in front of the FDA. Gratison was careful to note that VA will not move any of these treatments into standard clinical care until every applicable regulatory approval, including FDA sign-off and DEA rescheduling, is complete. Right now, all of these substances remain classified as Schedule I, which limits even basic research logistics like drug storage.
What Is the VA Doing to Prepare Before FDA Approval?
VA says it is not waiting around for a green light. Gratison described three priorities guiding every decision in this space: protecting veteran safety above all else, building a solid evidence base on which treatments work for which veterans, and positioning VA to be the first health system in the country ready to deliver these therapies once they are approved.
On the ground, that means VA has identified 10 facilities with the staff, space, and research experience to serve as early implementation and training sites. Those locations were chosen after what officials described as detailed quantitative and qualitative analysis of readiness, not a random pick. Several lawmakers, including Rep. Mike Conaway, pointed out that the list skews toward the coasts, with representation in California and Connecticut but none yet in the Southeast. Wiechers responded that veteran safety, not geographic balance, drove the initial selection, and that lessons from these sites will guide a phased expansion nationally.
VA has also signed agreements with HHS and FDA to support clinical trial participation, researcher training, data sharing, and treatment evaluation. Those partnerships followed an April 2026 presidential executive order directing agencies to accelerate review of treatments for serious mental illness.
Training is where things get labor intensive. Officials testified that providers at these 10 sites will need more than classroom instruction. They will need to physically sit in the room during a dosing session with an experienced clinician before they can lead one themselves, since a single psilocybin or MDMA session can run six to eight hours.
Why Are Veterans Groups Pushing for Readiness Now?
Veterans organizations made clear during the hearing that enthusiasm for psychedelic research should not be mistaken for confidence in the rollout plan. The VFW’s written testimony argues that VA needs to begin preparing now for the possibility of approval, covering workforce needs, provider training, facility capacity, geographic access, staffing, and payment policy, with specific attention to rural and underserved veterans.
Dr. States, testifying on the second panel, put it in personal terms. A combat veteran who receives all of his own care through VA, States told the subcommittee about losing a Navy corpsman in Afghanistan and said the lesson he carries is that the mission comes down to people, not paperwork. He warned lawmakers not to confuse activity with accomplishment: a study opening or an agency signing an agreement is progress, but it is not the same as a veteran actually getting treated.
Several members raised the same worry that applies to any new, in-demand treatment: a wave of wellness clinics marketing themselves to veterans once approval happens, much like what occurred after ketamine entered off-label use for depression. Brownley specifically asked VA to develop clear criteria for any community provider that wants to join its network, along with oversight mechanisms for patient safety and quality of care.
Dr. Halfond of the American Psychological Association outlined what she called non-negotiables for any care model: full informed consent treated as an ongoing conversation rather than a signature, licensed mental health providers involved at every stage, trauma-informed protocols with clear boundaries, and substantive follow-up that tracks suicidality, functioning, and adverse events over time.
What Could Stand in the Way of a Smooth Rollout?
Workforce capacity came up more than almost any other topic. Rep. Goodlander cited VA data showing more than 23,000 employees left the agency between January 2025 and July 2026, including over 1,600 doctors and nearly 400 psychologists. Dr. Halfond noted a loss of roughly 300 psychologist positions over the same stretch. That attrition sits uncomfortably next to a treatment model that requires extended, one-on-one, highly trained staff time.
Regulatory sequencing is its own hurdle. Gratison outlined the steps that have to happen after FDA approval: the DEA has to reschedule the compound out of Schedule I, and then individual states have to follow with their own rescheduling before the drug becomes commercially available. Dr. Coe’s testimony added that FDA-required risk evaluation and mitigation strategies, known as REMS, will likely dictate provider certification standards and distribution limits once a drug clears approval.
Dr. Niciu raised a more scientific obstacle: classic placebo-controlled trials are hard to run on drugs with such obvious, immediate effects. His research team at the University of Iowa has experimented with comparing psilocybin against ketamine, another active drug, rather than an inert placebo, specifically to reduce the chance that patients or researchers can guess who received what.
Funding is murkier than it might appear. Gratison confirmed that the fiscal year 2027 budget did not include a specific line item for psychedelic therapy readiness, though he maintained VA has the resources it needs for now. That answer did not fully satisfy lawmakers pressing for a concrete staffing and cost breakdown.
What Happens Next in Washington?
Brownley closed the hearing by calling for “vigorous oversight” once any treatment clears FDA review, specifically tied to whether VA can actually staff up in time. Miller-Meeks, for her part, framed the stakes in blunt terms: the measure of success will not be how many studies get published or how many pilot sites open, but whether veterans’ lives actually improve.
Gratison committed to delivering a staffing plan for the 10 facilities to the committee within 30 days, along with a list identifying those sites. Lawmakers from both parties indicated this will not be the last hearing on the subject, and several, including Rep. Jack Bergman, pressed for interagency coordination between VA, HHS, FDA, DEA, and the Department of Justice to avoid the kind of bureaucratic delay that has slowed past treatment rollouts, like the multi-year wait for insurance billing codes after ketamine’s 2019 approval.
For now, the message from both VA officials and outside advocates lands on the same point from different directions. The science has advanced enough that FDA approval looks plausible within the next year. But turning that green light into real care for a veteran in a VA waiting room will take infrastructure, staffing, and oversight that we still have to build.
For more coverage on where cannabis and emerging drug policy intersect with veterans and everyday consumers, check out our cannabis news section.
Frequently Asked Questions
Yes. The VFW’s testimony for the November 18, 2026 hearing cites 20 active VA clinical trials on psychedelic therapies backed by more than $23 million in external funding, while a VA official separately testified that 21 active studies were underway as of September 2026.
VA estimated roughly 180,000 veterans could meet eligibility criteria on day one of approval, based on about 2.1 million veterans currently diagnosed with PTSD, major depressive disorder, or treatment-resistant depression, filtered through the same standards used in its research trials.
Three compounds, MDMA, psilocybin, and ibogaine, currently have pending new drug applications before the FDA. VA has said it will not move any psychedelic treatment into standard clinical care until all required approvals, including DEA rescheduling, are finalized.
VA has identified 10 facilities to serve as early implementation and training sites, signed data-sharing and research agreements with HHS and FDA, and is building clinician training pathways that require hands-on experience, not just classroom instruction, before providers can lead treatment sessions.
Groups like the VFW point to the VA’s shrinking clinical workforce, noting that more than 23,000 employees left between January 2025 and July 2026. They argue that leaders must lock in facility, staffing, and safety protocols now so a veteran’s access does not depend on where they happen to live.
- Cannabis Rescheduling Is Coming. Is Your Financial House Ready?
- VA Official Says Psychedelic-Assisted Therapy Has More Bipartisan Support In Congress Than Marijuana
- The VA Funds First Study on Psychedelic-Assisted Therapy for Veterans Since the 1960s
- New VA Podcast Discusses Psychedelic Assisted Therapy On First Episode
- VA Alerts Veterans Cannabis Use Still Illegal at Federal Level Despite Ohio Legalization